NCT03280641

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,194 (actual)
• Sponsor: Wuhan Asia Heart Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: —

Summary

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

Detailed description

Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.

Conditions

• Atrial Fibrillation
• Strokes Thrombotic

Interventions

Type	Name	Description
DRUG	Dabigatran Etexilate 110mg	Dabigatran Etexilate 110mg, BID
DRUG	Warfarin Sodium	Target INR:1.6-3.0

Timeline

• Start date: 2015-08-09
• Primary completion: 2017-07-30
• Completion: 2017-09-01
• First posted: 2017-09-12
• Last updated: 2017-09-12

Locations

1 site across 1 country: China